falseQ2--12-310001755237http://fasb.org/us-gaap/2023#QualifiedPlanMember0001755237us-gaap:RetainedEarningsMember2022-04-012022-06-300001755237cycn:TisentoTherapeuticsHoldingsIncMemberus-gaap:SubsequentEventMember2023-07-280001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001755237us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001755237us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001755237us-gaap:RestrictedStockUnitsRSUMember2022-12-3100017552372023-03-310001755237cycn:LicensedRoomMember2022-01-012022-06-300001755237us-gaap:LicenseAndServiceMember2023-01-012023-06-300001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2023-06-3000017552372021-07-012022-12-310001755237us-gaap:CommonStockMember2022-12-310001755237us-gaap:RetainedEarningsMember2023-03-310001755237us-gaap:LeaseholdImprovementsMember2022-12-310001755237us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001755237cycn:AkbeiaSupplyAgreementMember2022-01-012022-06-300001755237us-gaap:RetainedEarningsMember2023-04-012023-06-300001755237us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001755237us-gaap:EmployeeStockOptionMember2023-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001755237us-gaap:CommonStockMember2022-03-310001755237cycn:WeworkMember2021-05-310001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001755237us-gaap:RetainedEarningsMember2023-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-3100017552372022-03-310001755237cycn:CurrentWorkforceReductionsMembercycn:October2022CurrentWorkforceReductionsMember2022-10-062022-10-060001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2020-09-032020-09-030001755237us-gaap:RetainedEarningsMember2021-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300001755237us-gaap:RetainedEarningsMember2022-06-3000017552372023-01-012023-03-310001755237cycn:WorkforceReductionPlanMember2022-12-310001755237us-gaap:SeriesAPreferredStockMember2023-03-310001755237us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001755237us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001755237cycn:WorkforceReductionPlanMember2023-06-3000017552372021-12-310001755237us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001755237us-gaap:CommonStockMember2023-03-3100017552372022-01-012022-06-300001755237us-gaap:CommonStockMember2022-01-012022-03-310001755237srt:MaximumMemberus-gaap:PerformanceSharesMember2023-01-012023-06-300001755237us-gaap:CommonStockMember2023-01-012023-03-310001755237us-gaap:OfficeEquipmentMember2023-06-300001755237us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001755237us-gaap:RetainedEarningsMember2022-03-310001755237us-gaap:LeaseholdImprovementsMember2023-06-300001755237us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001755237us-gaap:AdditionalPaidInCapitalMember2021-12-3100017552372023-07-2400017552372022-06-300001755237us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001755237srt:MinimumMemberus-gaap:PerformanceSharesMember2023-01-012023-06-3000017552372020-09-1500017552372022-01-012022-03-310001755237us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001755237us-gaap:RetainedEarningsMember2022-01-012022-03-310001755237us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001755237cycn:CyclerionSecuritiesCorporationMember2019-11-150001755237us-gaap:RestrictedStockUnitsRSUMember2023-06-300001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2023-01-012023-06-300001755237cycn:LicensedRoomMember2023-01-012023-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001755237us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001755237us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001755237cycn:AkbeiaSupplyAgreementMember2023-01-012023-06-300001755237us-gaap:PreferredStockMember2023-04-012023-06-300001755237srt:MaximumMember2023-01-012023-06-300001755237cycn:WorkforceReductionPlanMember2023-01-012023-06-300001755237us-gaap:RetainedEarningsMember2023-01-012023-03-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001755237us-gaap:AdditionalPaidInCapitalMember2023-03-310001755237us-gaap:LicenseAndServiceMember2022-01-012022-06-300001755237srt:MinimumMember2023-01-012023-06-300001755237cycn:CyclerionSecuritiesCorporationMember2023-01-012023-06-300001755237cycn:SeriesaConvertiblePreferredStockMember2023-06-300001755237us-gaap:AdditionalPaidInCapitalMember2022-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300001755237srt:MaximumMembercycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2020-09-032020-09-030001755237us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001755237us-gaap:AdditionalPaidInCapitalMember2022-06-300001755237us-gaap:EmployeeStockOptionMember2023-04-012023-06-3000017552372023-06-300001755237us-gaap:OfficeEquipmentMember2022-12-310001755237us-gaap:IPOMember2020-07-2400017552372023-04-012023-06-300001755237us-gaap:CommonStockMember2023-06-300001755237us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001755237us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001755237us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001755237us-gaap:LicenseAndServiceMember2023-04-012023-06-300001755237us-gaap:AdditionalPaidInCapitalMember2023-06-300001755237cycn:AkbeiaSupplyAgreementMember2022-04-012022-06-300001755237us-gaap:RetainedEarningsMember2022-12-310001755237us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001755237us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001755237us-gaap:CommonStockMember2023-04-012023-06-300001755237us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001755237us-gaap:SubsequentEventMember2023-07-282023-07-280001755237us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001755237cycn:WeworkMember2022-08-010001755237us-gaap:PropertyPlantAndEquipmentMember2022-01-012022-06-300001755237us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001755237us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001755237us-gaap:LicenseAndServiceMember2022-04-012022-06-300001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001755237us-gaap:EmployeeStockOptionMember2022-01-012022-06-3000017552372022-04-012022-06-300001755237us-gaap:CommonStockMember2021-12-3100017552372022-12-310001755237us-gaap:CommonStockMember2022-06-300001755237us-gaap:AdditionalPaidInCapitalMember2022-03-310001755237us-gaap:PreferredStockMember2023-06-300001755237us-gaap:FairValueMeasurementsRecurringMember2023-06-300001755237us-gaap:PropertyPlantAndEquipmentMember2023-01-012023-06-300001755237us-gaap:PerformanceSharesMember2023-01-012023-06-300001755237us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001755237us-gaap:EmployeeStockOptionMember2022-12-310001755237us-gaap:FairValueMeasurementsRecurringMember2022-12-310001755237cycn:LicensedRoomMember2022-04-012022-06-300001755237us-gaap:CommonStockMember2022-04-012022-06-300001755237cycn:AkebiaResearchLicenseAgreementMember2021-06-032021-06-0300017552372023-01-012023-06-300001755237cycn:LicensedRoomMember2023-04-012023-06-30cycn:Employeesxbrli:pureutr:sqftxbrli:sharescycn:TradingDayiso4217:USDcycn:Employee
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2023
or
|
|
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number 001-38787
CYCLERION THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
Massachusetts (State or other jurisdiction of incorporation or organization) |
|
83-1895370 (I.R.S. Employer Identification No.) |
|
|
|
245 First Street, 18th Floor, Cambridge, Massachusetts (Address of principal executive offices) |
|
02142 (Zip Code) |
(857) 327-8778
Registrant’s Telephone Number, Including Area Code
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, no par value |
|
CYCN |
|
The Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
Large accelerated filer ☐ |
|
Accelerated filer ☐ |
|
|
|
Non-accelerated filer ☒ |
|
Smaller reporting company ☒ |
|
|
|
|
|
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 24, 2023, the registrant had 2,410,796 shares of common stock, no par value, outstanding.
CYCLERION PHARMACEUTICALS, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 2023
TABLE OF CONTENTS
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. All statements in this report, other than statements of historical facts, including statements about future events, financing plans, financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations, are forward-looking statements that involve certain risks and uncertainties. Use of the words “may,” “might,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,” “impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal” or the negative of those words or other similar expressions may identify forward-looking statements that represent our current judgment about possible future events, but the absence of these words does not necessarily mean that a statement is not forward-looking.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market and regulatory conditions and the following:
•there is substantial doubt regarding our ability to continue as a going concern;
•the timing, investment and associated activities involved in developing, obtaining regulatory approval for, launching and commercializing our product candidates;
•we may be deemed an investment company under the Investment Company Act of 1940, as amended, which, if we were required to register thereunder, would have a material adverse effect on us;
•the uncertainty as to any liquidity or monetizable value of our equity interest in Tisento, which faces all the risks of an early-stage pharmaceutical development company;
•our relationships with third parties, collaborators and our employees;
•our ability to execute our strategic priorities;
•our ability to finance our operations and business initiatives;
•the success of collaboration or license agreements of our product candidates;
•our ability to access capital, capabilities, and transactions necessary to advance the development of our assets;
•whether the praliciguat out-license will result in the creation of any therapies;
•whether any development, regulatory, and commercialization milestones or royalty payments provided for in the agreement with Akebia (as defined below in Note 1 to the Condensed Consolidated Financial Statements) will be achieved;
•the impact on our business of workforce and expense reduction initiatives;
•our or our partners' plans with respect to the development, manufacture or sale of our product candidates and the associated timing thereof, including the design and results of pre-clinical and clinical studies;
•the safety profile and related adverse events of our product candidates;
•the efficacy and perceived therapeutic benefits of our product candidates, their potential indications and their market potential;
•U.S. and non-U.S. regulatory requirements for our product candidates, including any post-approval development and regulatory requirements, and the ability of our product candidates to meet such requirements;
3
•our ability to attract and retain employees needed to execute our business plans and strategies and our ability to manage the impact of any loss of key employees;
•our ability to obtain and maintain intellectual property protection for our product candidates and the strength thereof;
•our future financial performance, revenues, expense levels, payments, cash flows, profitability, tax obligations, capital raising and liquidity sources, real estate needs and concentration of voting control, as well as the timing and drivers thereof, and internal control over financial reporting;
•our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;
•the impact of government regulation in the life sciences industry, particularly with respect to healthcare reform;
•we could be delisted from Nasdaq;
•trends and challenges in the markets for our potential products.
See the “Risk Factors” section in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and elsewhere in this Quarterly Report on Form 10-Q for a further description of these and other factors. We caution you that the risks, uncertainties, and other factors referenced above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made and, except as required by applicable law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.
4
Cyclerion Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
5,641 |
|
|
$ |
13,382 |
|
Accounts receivable |
|
|
— |
|
|
|
96 |
|
Prepaid expenses |
|
|
1,044 |
|
|
|
805 |
|
Other current assets |
|
|
428 |
|
|
|
537 |
|
Total current assets |
|
|
7,113 |
|
|
|
14,820 |
|
Operating lease right-of-use asset |
|
|
1,125 |
|
|
|
1,218 |
|
Other assets |
|
|
1,859 |
|
|
|
2,041 |
|
Total assets |
|
$ |
10,097 |
|
|
$ |
18,079 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,864 |
|
|
$ |
2,970 |
|
Accrued research and development costs |
|
|
620 |
|
|
|
2,275 |
|
Accrued expenses and other current liabilities |
|
|
2,463 |
|
|
|
2,382 |
|
Total current liabilities |
|
|
4,947 |
|
|
|
7,627 |
|
Commitments and contingencies (Note 6) |
|
|
— |
|
|
|
— |
|
Stockholders' equity |
|
|
|
|
|
|
Preferred shares, no par value, 500,000 shares authorized and 351,037 series A convertible preferred stock issued and outstanding at June 30, 2023 |
|
|
— |
|
|
|
— |
|
Common stock, no par value, 20,000,000 shares authorized and 2,407,796 issued and outstanding at June 30, 2023 and 20,000,000 shares authorized and 2,175,936 issued and outstanding at December 31, 2022 (*) |
|
|
— |
|
|
|
— |
|
Paid-in capital |
|
|
275,455 |
|
|
|
269,626 |
|
Accumulated deficit |
|
|
(270,289 |
) |
|
|
(259,154 |
) |
Accumulated other comprehensive loss |
|
|
(16 |
) |
|
|
(20 |
) |
Total stockholders' equity |
|
|
5,150 |
|
|
|
10,452 |
|
Total liabilities and stockholders' equity |
|
$ |
10,097 |
|
|
$ |
18,079 |
|
*Adjusted retroactively for reverse stock split - see Note 1
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Cyclerion Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands except per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from development agreement |
|
|
— |
|
|
|
72 |
|
|
|
— |
|
|
|
297 |
|
Revenue from grants |
|
|
— |
|
|
|
234 |
|
|
|
— |
|
|
|
720 |
|
Total revenues |
|
|
— |
|
|
|
306 |
|
|
|
— |
|
|
|
1,017 |
|
Cost and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
886 |
|
|
|
10,218 |
|
|
|
4,659 |
|
|
|
19,961 |
|
General and administrative |
|
|
3,357 |
|
|
|
3,521 |
|
|
|
6,626 |
|
|
|
7,473 |
|
Total cost and expenses |
|
|
4,243 |
|
|
|
13,739 |
|
|
|
11,285 |
|
|
|
27,434 |
|
Loss from operations |
|
|
(4,243 |
) |
|
|
(13,433 |
) |
|
|
(11,285 |
) |
|
|
(26,417 |
) |
Interest and other income, net |
|
|
62 |
|
|
|
45 |
|
|
|
150 |
|
|
|
51 |
|
Net loss |
|
$ |
(4,181 |
) |
|
$ |
(13,388 |
) |
|
$ |
(11,135 |
) |
|
$ |
(26,366 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share (*) |
|
$ |
(1.83 |
) |
|
$ |
(6.16 |
) |
|
$ |
(5.00 |
) |
|
$ |
(12.14 |
) |
Weighted average shares used in calculating: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
|
2,282 |
|
|
|
2,173 |
|
|
|
2,229 |
|
|
|
2,172 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,181 |
) |
|
$ |
(13,388 |
) |
|
$ |
(11,135 |
) |
|
$ |
(26,366 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment loss |
|
|
3 |
|
|
|
(1 |
) |
|
|
4 |
|
|
|
(2 |
) |
Comprehensive loss |
|
$ |
(4,178 |
) |
|
$ |
(13,389 |
) |
|
$ |
(11,131 |
) |
|
$ |
(26,368 |
) |
*Adjusted retroactively for reverse stock split - see Note 1
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Cyclerion Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Paid-in |
|
|
Accumulated |
|
|
Accumulated other comprehensive |
|
|
Total Stockholders’ |
|
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
deficit |
|
|
loss |
|
|
equity |
|
Balance at December 31, 2021 |
|
|
2,170,509 |
|
|
$ |
— |
|
|
$ |
263,345 |
|
|
$ |
(215,076 |
) |
|
$ |
(23 |
) |
|
$ |
48,246 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(12,978 |
) |
|
|
— |
|
|
|
(12,978 |
) |
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan |
|
|
1,909 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan |
|
|
— |
|
|
|
— |
|
|
|
1,476 |
|
|
|
— |
|
|
|
— |
|
|
|
1,476 |
|
Share‑based compensation expense related to issuance of stock options to non-employees |
|
|
|
|
|
|
|
|
291 |
|
|
|
|
|
|
|
|
|
291 |
|
Foreign currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
(1 |
) |
Balance at March 31, 2022 |
|
|
2,172,418 |
|
|
$ |
— |
|
|
$ |
265,112 |
|
|
$ |
(228,054 |
) |
|
$ |
(24 |
) |
|
$ |
37,034 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,388 |
) |
|
|
— |
|
|
|
(13,388 |
) |
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan |
|
|
1,574 |
|
|
|
— |
|
|
|
17 |
|
|
|
— |
|
|
|
— |
|
|
|
17 |
|
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan |
|
|
— |
|
|
|
— |
|
|
|
1,410 |
|
|
|
— |
|
|
|
— |
|
|
|
1,410 |
|
Share‑based compensation expense related to issuance of stock options to non-employees |
|
|
|
|
|
|
|
|
289 |
|
|
|
|
|
|
|
|
|
289 |
|
Foreign currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
(1 |
) |
Balance at June 30, 2022 |
|
|
2,173,992 |
|
|
|
— |
|
|
|
266,828 |
|
|
|
(241,442 |
) |
|
|
(25 |
) |
|
|
25,361 |
|
7
Cyclerion Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock (*) |
|
|
Preferred Stock |
|
|
Paid-in |
|
|
Accumulated |
|
|
Accumulated other comprehensive |
|
|
Total Stockholders’ |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
deficit |
|
|
loss |
|
|
equity |
|
Balance at December 31, 2022 |
|
|
2,175,936 |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
269,626 |
|
|
$ |
(259,154 |
) |
|
$ |
(20 |
) |
|
$ |
10,452 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6,954 |
) |
|
|
— |
|
|
|
(6,954 |
) |
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan |
|
|
309 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
416 |
|
|
|
— |
|
|
|
— |
|
|
|
416 |
|
Share‑based compensation expense related to issuance of stock options to non-employees |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
Foreign currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
1 |
|
Balance at March 31, 2023 |
|
|
2,176,245 |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
270,052 |
|
|
$ |
(266,108 |
) |
|
$ |
(19 |
) |
|
$ |
3,925 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,181 |
) |
|
|
— |
|
|
|
(4,181 |
) |
Issuance of common stock |
|
|
225,000 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,953 |
|
|
|
— |
|
|
|
— |
|
|
|
1,953 |
|
Issuance of preferred shares |
|
|
— |
|
|
|
— |
|
|
|
351,037 |
|
|
|
— |
|
|
|
3,047 |
|
|
|
— |
|
|
|
— |
|
|
|
3,047 |
|
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan |
|
|
6,618 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
373 |
|
|
|
— |
|
|
|
— |
|
|
|
373 |
|
Share‑based compensation expense related to issuance of stock options to non-employees |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
Foreign currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3 |
|
|
|
3 |
|
Fractional shares issuance |
|
|
(67 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance at June 30, 2023 |
|
|
2,407,796 |
|
|
|
— |
|
|
|
351,037 |
|
|
|
— |
|
|
$ |
275,455 |
|
|
$ |
(270,289 |
) |
|
$ |
(16 |
) |
|
$ |
5,150 |
|
*Adjusted retroactively for reverse stock split - see Note 1
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
Cyclerion Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
Net loss |
|
$ |
(11,135 |
) |
|
$ |
(26,366 |
) |
Adjustments to reconcile net loss to net cash (used in) operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
|
— |
|
|
|
65 |
|
Share-based compensation expense |
|
|
805 |
|
|
|
3,466 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
96 |
|
|
|
(127 |
) |
Related party accounts receivable |
|
|
— |
|
|
|
— |
|
Prepaid expenses |
|
|
(239 |
) |
|
|
281 |
|
Other current assets |
|
|
109 |
|
|
|
(14 |
) |
Operating lease assets |
|
|
93 |
|
|
|
92 |
|
Other assets |
|
|
182 |
|
|
|
183 |
|
Accounts payable |
|
|
(1,106 |
) |
|
|
939 |
|
Accrued research and development costs |
|
|
(1,655 |
) |
|
|
(1,594 |
) |
Accrued expenses and other current liabilities |
|
|
81 |
|
|
|
(578 |
) |
Net cash (used in) operating activities |
|
|
(12,769 |
) |
|
|
(23,653 |
) |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
Proceeds from stock purchase agreement |
|
|
5,000 |
|
|
|
— |
|
Proceeds from exercises of stock options and ESPP |
|
|
24 |
|
|
|
17 |
|
Net cash provided by financing activities |
|
|
5,024 |
|
|
|
17 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
4 |
|
|
|
(2 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(7,741 |
) |
|
|
(23,638 |
) |
Cash, cash equivalents and restricted cash, beginning of period |
|
|
13,382 |
|
|
|
53,961 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
5,641 |
|
|
$ |
30,323 |
|